Brieuc Sautois

Centre Hospitalier Chrétien — Belgium

Medicine · Health Sciences

19h-index3.6kcitations148works2.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(55), PARP inhibition in cancer therapy(48), Cancer Treatment and Pharmacology(13), Radiopharmaceutical Chemistry and Applications(12), Prostate Cancer Diagnosis and Treatment(11)

Publications148 total

Stage Migration on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Comparison to Conventional Imaging in Patients with High-risk Prostate Cancer Referred for Radiation Therapy: Results from the Phase 2/3 THUNDER Trial
European Urology Oncology·2025Open Access
[PARP inhibitors (poly-ADP-ribose polymerase) : newcomers in the management of prostate cancers].
PubMed·2025
Assessing Interlesional Tumor Response and Patient Outcomes with Sequential PSMA PET/CT in Metastatic Castration-Resistant Prostate Cancer
Journal of Nuclear Medicine·2025Open Access
Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial
Journal for ImmunoTherapy of Cancer·2025· 2 citedOpen Access
4996 PSMA PET/CT Stage Migration and Genomic Classifier Scores in High-Risk Prostate Cancer: First-Year Results from the THUNDER Trial (NCT06282588)
Radiotherapy and Oncology·2025
[Recommendations for the management of kidney cancer in 2025].
PubMed·2025
Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial
European Urology Oncology·2025· 2 citedOpen Access
[Testicular seminoma revealed by hypergonadotropic hypogonadism].
PubMed·2024
Characterization of exclusive rib lesions detected by [68Ga]Ga-PSMA-11 PET/CT
Nuclear Medicine Communications·2024· 2 citedOpen Access
1636P Health-related quality of life outcomes of androgen receptor pathway inhibitors versus taxanes versus standard of care in metastatic castration-resistant prostate cancer: Results from the ProBio trial
Annals of Oncology·2024
1619P Efficacy of carboplatin in patients with metastatic castration-resistant prostate cancer: Results from the biomarker-driven, randomised, outcome-adaptive ProBio trial
Annals of Oncology·2024· 2 cited
1623P Prognostic value of circulating tumour DNA fraction in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Annals of Oncology·2024Open Access
Author Correction: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial
Nature Medicine·2024Open Access
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial
Nature Medicine·2024· 18 citedOpen Access
Avelumab (A) as neoadjuvant therapy in patients (pts) with muscle-invasive urothelial carcinoma (MIUC): Survival data of AURA trial, Oncodistinct 004.
Journal of Clinical Oncology·2024· 8 cited
Mise au point et stratégies thérapeutiques dans le cancer de la prostate avancé et métastatique
Médecine Nucléaire·2023Open Access
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study
European Urology·2023· 79 citedOpen Access
Suppl Fig S2C from Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
2023Open Access
Data from Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
2023Open Access
Data from Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Georges Fillet(12), Wassim Abida(11), Ray McDermott(11), Emmanuel Seront(11), Alan H. Bryce(10), Darrin Despain(10), Yves Béguin(10), Simon P. Watkins(9), Akash Patnaik(8), Jeremy Shapiro(8), Andrew D. Simmons(8), Andrea Loehr(8), Simon Chowdhury(8), David Campbell(7), Nicholas J. Vogelzang(7), Charles J. Ryan(7), Axel Heidenreich(7), Karim Fizazi(7), Richard Bambury(6), Jingsong Zhang(6)